Patients with CKD are at high risk for adverse safety events because of the complexity of their care and impaired renal function. Using data from our observational study of predialysis patients with CKD enrolled in the Safe Kidney Care study, we estimated the baseline frequency of adverse safety events and determined to what extent these events co-occur. We examined patient-reported adverse safety incidents (class I) and actionable safety findings (class II), conditioned on participant use of drugs that might cause such an event, and we used association analysis as a data-mining technique to identify co-occurrences of these events. Of 267 participants, 185 (69.3%) had at least one class I or II event, 102 (38.2%) had more than one event, and 48 (18.0%) had at least one event from both classes. The adjusted conditional rates of class I and class II events ranged from 2.9 to 57.6 per 100 patients and from 2.2 to 8.3 per 100 patients, respectively. The most common conditional class I and II events were patient-reported hypoglycemia and hyperkalemia (serum potassium.5.5 mEq/L), respectively. Reporting of hypoglycemia (in patients with diabetes) and falling or severe dizziness (in patients without diabetes) were most frequently paired with other adverse safety events. We conclude that adverse safety events are common and varied in CKD, with frequent association between disparate events. Further work is needed to define the CKD "safety phenotype" and identify patients at highest risk for adverse safety events.
Providing safe medical care is a national priority, and substantial effort has been devoted to reducing medical errors and adverse safety events. [1] [2] [3] Predialysis patients with CKD have enhanced susceptibility to harm related to health care. 4, 5 Several factors account for this risk, including impaired renal function and altered drug clearance, along with comorbid conditions and frequent hospitalizations. [5] [6] [7] [8] Adverse safety events probably play a role in CKD progression, and strategies to reduce them may mitigate loss or disruption of renal function in many patients with CKD. 9 Although patients with CKD are often hospitalized, their care is largely delivered outside of the hospital. 9 There is little information on the frequency of adverse safety events among patients with CKD in the outpatient setting.
We examined patients with CKD enrolled in the ongoing Safe Kidney Care cohort study (NCT01407367), which attempts to determine the frequency of adverse safety events pertinent to the outpatient care of patients with CKD. The Safe Kidney Care study events reported in this analysis include patient-reported adverse safety incidents (class I), which are reported hazardous events or symptoms that study participants attribute to a medication. Actionable safety findings (class II) are hazardous clinical disturbances detected at study evaluations that have the potential for correction with treatment or medication modification. We also examine which class I and class II events are associated with other events within and between classes. Given the complex interaction between the heterogeneous array of potential adverse safety events and the limitations of using regression methods with such data, we used a data-mining technique known as association analysiscommonly used in genomic studies-to examine the interrelationship between these safety findings. [10] [11] [12] RESULTS Table 1 displays the frequency and adjusted rates of both class I and II adverse safety events among all 267 participants in the analysis cohort (unconditional), and also among participants who report use of medications from a drug class during the prior 30 days that can plausibly account for each respective event (conditional), adjusting for age, sex, African American race, diabetes, cancer, cardiovascular disease, GFR, annual household income, education level, marital status, and number of medications.
The most common class I event was self-reported hypoglycemia, with a higher adjusted rate conditional on use of diabetic medication within the last 30 days. Falling or severe dizziness was the second most common class I event. A high venous hemoglobin (using a value of 13.5 g/dl as a safety threshold) [13] [14] [15] was the most common class II event, but when conditional on use of an erythropoietic stimulating agent, no participant had this class II event. Hyperkalemia (serum potassium.5.5 mEq/L) was the next most common class II event, which rose in rank to the most common event in this class conditional on use of a drug that can lead to hyperkalemia (e.g., renin-angiotensin-aldosterone system blocker, potassiumsparing diuretic, or nonsteroidal anti-inflammatory drug). Table 2 lists characteristics of the 267 participants grouped by the occurrence and type of adverse safety event. One hundred eighty-five (69.3%) had at least one class I or II adverse safety event, and 48 (18.0%) had at least one adverse event in both categories. Participants with no event were more likely to be older, male, African American, and nondiabetic and to have a higher GFR but were less likely to have had cancer or cardiovascular disease. Those who did not experience any event took fewer medications. Figure 1 shows the distribution of study participants based on the number of conditional events they experienced in each category. Eighty-three (31.1%) participants experienced only one class I or II event, and 102 (38.2%) had multiple events from one or both classes. More study participants reported multiple class I events than class II events, with 78 (29.2%) and 12 (4.5%) for each class, respectively; 6 (2.3%) participants had two or more events with at least one event in both classes. Table 3 displays the results of the association analysis of adverse safety events among the 102 study participants who had the co-occurrence of two adverse safety events from the atrisk population of those with at least one event (n=185) and depicts several association analysis parameters. Support is a measure of how many participants experience the event pair expressed as a percentage of the whole sample. The occurrence of one event (antecedent) is used to predict another (consequent) event. Confidence is the frequency of co-occurrence divided by the occurrence of the designated antecedent in the sample and measures how much more likely it is for a consequent event to occur when the antecedent has occurred. The lift ratio is the ratio of the confidence to the expected confidence, where the latter is defined as the frequency of participants experiencing the consequent event (with or without the antecedent) as a percentage of the total sample of participants. Table  3 displays co-occurring event pairs observed at least twice in the sample, a lift ratio .1, and a P value ,0.05. Associations between class I events were the most common, with the highest frequency of co-occurrence (and support) between self-reported confusion and falling or severe dizziness. The class I event pair with the highest lift ratio was a report of bleeding with angioedema, followed by the paired report of nausea, vomiting, or diarrhea with rash. There are no significant associations solely among the class 2 events. For class I and class II events examined together, self-reported hypoglycemia had the most numerous co-occurrences with laboratory-based hypoglycemia. There was no trend in the distribution of associated events by stage 3a versus stage 3b-V CKD groups. Figure 2A displays a link graph depicting the inter-relationship of adverse safety events that co-occur with the most common (index) event of class I hypoglycemia among diabetic study participants with at least one event (n=136). No patients without diabetes reported hypoglycemia. Figure 2B displays the corresponding link graph in patients without diabetes who had at least one adverse safety event (n=49) and the events' cooccurring with the index event of class I falling or severe dizziness. In both figures, peripheral nodes represent the events that co-occur with the index, centrally located, event. The pairings with the highest support are in the 12 o'clock position and decline in a clockwise fashion. Class I and class II nodes have solid and dashed borders, respectively, with the frequency of participants with each event noted in the node. Both directions of the link between index and peripherally distributed events are shown with a designated arrow and the associated confidence. The boldness of the arrow depicts the strength of confidence.
The strongest support among patients with diabetes with adverse safety events was the pairing of the index event and a class I report of falling or severe dizziness (the second most common independently occurring class I event). Of the 42 patients with diabetes who reported falling or severe dizziness, there was a high degree of confidence that they would also experience hypoglycemia-69% of them reported the index event; conversely, of the 87 patients with diabetes who reported at least one episode of hypoglycemia, 33% reported falling or severe dizziness. The co-occurring pair with the second highest degree of support was a class I event of hyperkalemia with the index event. Both class II hyperglycemia and hypoglycemia had the strongest confidence relationship with the index event. If hyperglycemia (or hypoglycemia) was detected at the baseline study visit, 86% of these individuals also reported having had hypoglycemia. Additional adverse safety events with strong confidence relationships with the index event were confusion and low hemoglobin. Among the patients without diabetes depicted, class I hyperkalemia had the highest support with the index event of falling or severe dizziness. The pairing with the strongest confidence was class I edema with the index event such that two thirds of individuals with a report of edema reported the index event.
DISCUSSION
This analysis offers insight into the frequency and interrelationship of adverse safety events in ambulatory patients with CKD. The occurrence of these events ranged from sporadic to common but was frequent when considered in aggregate; this demonstrates the susceptibility of the CKD population to complications of medical care. The causal relationship between treatment, or medications, and the class I and II events as we define them is difficult to confirm, but by focusing our analysis on events that occur conditional on medications that could account for such events, we offer a potential causal link between treatment and adverse safety event with the risk for harmful consequences. There is no consensus on standards to gauge safety in CKD, and there are few tools with which to detect adverse safety Although there may be recall bias in elderly patients' reporting of class I events, the lower rate of adverse safety events in this group is sustained with class II events, which are ascertained in-center and are not subject to such a bias. Similarly, the lower rate of events reported among African American patients is consistent with our previous finding of fewer medication errors among African Americans with CKD. We previously hypothesized that this was related to higher serum creatinine values among blacks relative to whites at any level of GFR, which serves as a prompt for more cautious care. 16 Prior studies of safety in CKD used large administrative data sets 4, 17 or clinical trial data to examine the frequency of selected laboratory disturbances, 18-21 but these analyses could not examine patient-reported events or be used for more extensive clinical assessments. Additional studies have also looked at the prevalence of medication errors in CKD, [22] [23] [24] [25] [26] [27] [28] [29] but most have not examined the link between medication use and adverse safety events. This study provides a more patient-centered evaluation of safety in CKD and the conditionality of two key dimensions of adverse safety events on medication use and how events in these distinct dimensions potentially inter-relate.
The results of this descriptive study should be interpreted with the study limitations in mind. The design of the Safe Kidney Care study and the means by which adverse safety events are measured has the potential of biased detection because the instruments used are based on expected adverse consequences of treatments common in CKD, but they may overlook unexpected safety incidents in the disease population. Nevertheless, the study identifies unrecognized connections between detected adverse safety events, some of which require further exploration as to the causal link. The relatively small sample size limits the robustness of rate estimates, especially for adverse safety events that are relatively uncommon. Although more precise estimates of the frequency of such events can be obtained from larger administrative or population-based samples, there is a tradeoff with the degree of detail obtained from a study on the scale of the Safe Kidney Care cohort. The relatively modest sample size limits the ability to demonstrate statistically significant associations among a heterogeneous array of adverse safety events within individuals; however, association analysis, while infrequently used in chronic disease epidemiology, [30] [31] [32] provides a novel way to offer preliminary evidence of such relationships. Finally, because these data are cross-sectional, we are unable to show any causative relationships in our analysis, although future longitudinal analyses from the Safe Kidney Care study will assist in delineating causal pathways.
Determining the range and frequency of adverse safety events in the CKD population, as well as the relationship these events have with each other, confirms the assertion that patients with CKD are at risk for harm from their management along with that anticipated from the biology of their disease. The findings of this study represent a first step in defining a safety "phenotype" in CKD, and mapping the safety phenotype in CKD offers new opportunities to modify treatment approaches and alter the high rate of adverse outcomes common in CKD.
CONCISE METHODS

Study Population
The analysis includes participants of the Safe Kidney Care study, which is an ongoing observational study designed to track the frequency of disease-specific adverse safety events longitudinally in predialysis CKD (ClinicalTrials.gov NCT01407367). Inclusion in the Safe Kidney Care cohort requires participants to be age 21 years or older, with two measures of GFR-obtained using the abbreviated Modification of Diet in Renal Disease equation 33 -that are ,60 ml/min per 1.73 m 2 at least 90 days apart, and both obtained ,18 months before enrollment. Patients who are expected to initiate dialysis or die in the 12 months are excluded. A total of 108 eligible patients were first enrolled into phase I of the cohort, which pilots a medical alert device Table 3 . Association analysis of study participants who had two or more class I or II adverse safety events (n=102) from the at-risk sample of participants with at least one event (n=185)
Event ( Support: participants with a co-occurrence of the named events divided by the at-risk sample with at least one event (n=185). Confidence: frequency of participants with co-occurrence of events (a and b) divided by the frequency of participants with the designated antecedent event. Expected confidence: frequency of participants with the consequent event divided by the at-risk sample (not shown). Lift ratio: confidence divided by the expected confidence for the at-risk sample (note: lift ratio is identical regardless of the choice of antecedent and consequent designation in a pair).
designed to increase the recognition of CKD. Enrollment then commenced for phase II, based on the same inclusion and exclusion criteria cited, and included participants who underwent identical baseline evaluations and longitudinal follow-up but were not given the medical alert device. This report includes data from the baseline visit of all study participants from phase I and phase II enrolled in the study before June 18, 2013. The study was approved by the University of Maryland, Baltimore, Institutional Review Board and the Baltimore Veterans Affairs Research and Development R&D committees.
Study Safety Assessments
This descriptive analysis includes two categories of adverse safety events determined at baseline assessment. Patient-reported adverse safety incidents (class I) are ascertained from a baseline self-reported safety event questionnaire developed for the Safe Kidney Care study, which asks participants whether, over the prior 12 months, they experienced hypoglycemia or hyperkalemia requiring treatment or change in therapy or diet, along with other adverse safety incidents that they attribute to an administered medication or treatment. The potential incidents, in addition to hypoglycemia and hyperkalemia cited on the self-reported safety event questionnaire, include falling or severe dizziness; bleeding; angioedema; confusion or inability to think clearly; nausea, vomiting, and/or diarrhea; new or worsening ankle swelling; muscle weakness or muscle cramps; and skin rash (see Supplemental Appendix). Our definition for self-reported hypoglycemia was based on a composite of whether a participant answered "yes" to question 1a or 1b or both, and for falling and severe dizziness whether participant answered "yes" to question 2a or 2b on the questionnaire. Actionable safety findings (class II) are potentially hazardous abnormalities in baseline laboratory and vital sign parameters associated with concomitant treatment with a drug known to cause such a disturbance, and with the potential to be corrected with discontinuation or modification in the dose of the suspect agent or some other treatment (e.g., low pulse in the setting of a b-blocker).
Phlebotomy is performed at baseline visit after a fast of 6 hours or more and provides measurements of serum glucose, potassium, venous hemoglobin, and creatinine. The baseline vital sign assessment includes seated BP and pulse obtained after a 5-minute quiet period and a repeat measurement of BP and pulse after standing for 2 minutes (Omron HEM-907XL; Wake Forest, IL).
Covariates
Additional factors included demographic characteristics (age, sex, African American race, diabetes, cancer, cardiovascular disease, GFR, annual household income, education level, marital status, and number of medications). Medication use was recorded for up to 30 days before the baseline study assessment. The number of medications recorded reflected all participants' drug entries. Combination products are listed as individual constituents unless the drug is available only as a combination. Baseline renal function was measured using the serum creatinine obtained at the study visit; the abbreviated Modification of Diet in Renal Disease equation was used to calculate the estimated GFR.
Statistical Analyses
Study participants were classified as having a class I and class II adverse safety event, both unconditionally in all participants and conditionally according to whether participants were prescribed a drug from a class that could potentially cause such a complication. All analyses subsequent to those conducted for descriptive purposes used the conditional determination and the restricted sample at risk for each respective class I and II adverse safety event. Categorical variables are reported with number and percentage of total number. Continuous variables are reported with mean and SD or median and interquartile range. All analyses were done using SAS software, version 9.3, and SAS Enterprise Miner, version 12.1 (SAS Institute, Inc., Cary, NC).
Because of the small counts of several events, we used principal component analysis to calculate corresponding adjusted rates. This statistical technique converts a set of observed variables into a set of uncorrelated variables called principal components, wherein the first several principal components can explain most of the variation in the original variables. 34, 35 Therefore, we used the first principal component, which accounts for the largest variation in the original patient characteristic variables, to adjust for multiple patient characteristics in the logistic regression models used to report adjusted rates.
We used association analysis to examine the inter-relationships between the heterogeneous array of events reported both within and between class I and II adverse safety events. This data-mining technique is commonly applied to complex data, such as those found in genomics, but is less commonly used in chronic disease epidemiology, [30] [31] [32] to identify genetic polymorphisms that have a significant association with disease manifestations. [10] [11] [12] A similar method, market basket analysis, is used with large retail marketing data sets to delineate shopping patterns and predict purchasing behavior. 36 Using the association node in SAS Enterprise Miner, we were able to determine all single-dimensional affinities that occur among the conditional adverse safety events identified in our data set. 37 Association analyses do not typically involve statistical hypothesis testing; however, co-occurrence can be expressed in contingency tables, allowing for the calculation of chi-squared statistics and P values. 38 Because all associations in single-dimensional association analysis can be bi-directional, we treated both factors in a co-occurrence as the antecedent event and display both confidence values. We also derived link graphs from the association analysis 39 exhibiting the relationship between the index adverse event among patients with diabetes and patients without diabetes, which were class I reports of hypoglycemia and falling or severe dizziness, respectively.
